{"InvestigatorsIMPORTANCE": [0], "Phase": [1], "3": [2], "trials": [3], "have": [4], "not": [5], "compared": [6, 411], "semaglutide": [7, 147, 209, 285, 327, 381, 393, 410], "and": [8, 21, 40, 138, 162, 187, 201, 272, 320, 354, 382, 394, 421], "liraglutide,": [9, 34, 125, 415], "glucagon-like": [10], "peptide-1": [11], "analogues": [12], "available": [13], "for": [14, 208, 375, 419], "weight": [15, 205, 278, 324, 428], "management.OBJECTIVE": [16], "To": [17], "compare": [18], "the": [19, 165, 270], "efficacy": [20], "adverse": [22, 386], "event": [23], "profiles": [24], "of": [25, 74, 84, 146, 158, 194, 229, 312, 331, 371], "once-weekly": [26, 109, 408], "subcutaneous": [27, 33, 110, 124, 409, 414], "semaglutide,": [28, 111], "2.4": [29, 112, 144], "mg,": [30], "vs": [31, 210, 215, 232, 286, 328, 333, 344, 356], "once-daily": [32, 123, 413], "3.0": [35, 126, 156], "mg": [36, 113, 127, 145, 157], "(both": [37], "with": [38, 45, 80, 92, 220, 284, 288, 303, 326, 380, 384, 392, 396, 402, 412], "diet": [39, 137, 420], "physical": [41, 139, 422], "activity),": [42], "in": [43, 78, 184, 425], "people": [44], "overweight": [46, 403], "or": [47, 86, 88, 90, 94, 119, 122, 133, 196, 199, 203, 315, 318, 322, 404], "obesity.DESIGN,": [48], "SETTING,": [49], "AND": [50, 176, 398], "PARTICIPANTS": [51], "Randomized,": [52], "open-label,": [53, 219], "68-week,": [54], "phase": [55], "3b": [56], "trial": [57], "conducted": [58], "at": [59, 212, 430], "19": [60], "US": [61], "sites": [62], "from": [63, 280], "September": [64, 67], "2019": [65], "(enrollment:": [66], "11-November": [68], "26)": [69], "to": [70, 107, 142, 154, 297, 341, 352, 364, 417], "May": [71, 76], "2021": [72], "(end": [73], "follow-up:": [75], "11)": [77], "adults": [79, 401], "body": [81, 185, 255, 262], "mass": [82, 263], "index": [83], "30": [85], "greater": [87, 91, 310, 427], "27": [89], "1": [93], "more": [95, 204, 323], "weight-related": [96], "comorbidities,": [97], "without": [98, 406], "diabetes": [99], "(N": [100], "=": [101, 117, 131, 172], "338).INTERVENTIONS": [102], "Participants": [103], "were": [104, 169, 192, 218, 235, 378, 388], "randomized": [105, 242], "(3:1:3:1)": [106], "receive": [108, 149], "(16-week": [114], "escalation;": [115, 129], "n": [116, 130], "126),": [118], "matching": [120, 134], "placebo,": [121, 135], "(4-week": [128], "127),": [132], "plus": [136], "activity.Participants": [140], "unable": [141, 153], "tolerate": [143, 155], "could": [148, 163], "1.7": [150], "mg;": [151], "participants": [152, 243, 332, 372], "liraglutide": [159, 211, 216, 289, 329], "discontinued": [160], "treatment": [161, 222, 374], "restart": [164], "4-week": [166], "titration.Placebo": [167], "groups": [168, 223], "pooled": [170, 233, 304], "(n": [171], "85).": [173], "MAIN": [174], "OUTCOMES": [175], "MEASURESThe": [177], "primary": [178], "end": [179, 190, 238], "point": [180], "was": [181, 282, 306], "percentage": [182, 292], "change": [183, 279, 302], "weight,": [186, 256], "confirmatory": [188], "secondary": [189, 237], "points": [191, 293], "achievement": [193], "10%": [195, 314], "more,": [197, 200, 316, 319], "15%": [198, 317], "20%": [202, 321], "loss,": [206], "assessed": [207], "week": [213], "68.Semaglutide": [214], "comparisons": [217], "active": [221, 230], "double-blinded": [224], "against": [225], "matched": [226], "placebo": [227, 234, 305], "groups.Comparisons": [228], "treatments": [231], "supportive": [236], "points.": [239], "RESULTSOf": [240], "338": [241], "(mean": [244], "[SD]": [245, 254, 261], "age,": [246], "49": [247], "[13]": [248], "years;": [249], "265": [250], "women": [251], "[78.4%];": [252], "mean": [253, 260, 277], "104.5": [257], "[23.8]": [258], "kg;": [259], "index,": [264], "37.5": [265], "[6.8]),": [266], "319": [267], "(94.4%)": [268], "completed": [269, 275], "trial,": [271], "271": [273], "(80.2%)": [274], "treatment.The": [276], "baseline": [281], "-15.8%": [283], "-6.4%": [287], "(difference,": [290], "-9.4": [291], "[95%": [294], "CI,": [295, 339, 350, 362], "-12.0": [296], "-6.8];": [298], "P": [299, 368], "<": [300, 369], ".001);weight": [301], "-1.9%.Participants": [307], "had": [308], "significantly": [309, 426], "odds": [311], "achieving": [313], "loss": [325, 429], "(70.9%": [330], "25.6%": [334], "[odds": [335, 346, 358], "ratio,": [336, 347, 359], "6.3": [337], "{95%": [338, 349, 361], "3.5": [340, 363], "11.2}],": [342], "55.6%": [343], "12.0%": [345], "7.9": [348], "4.1": [351], "15.4}],": [353], "38.5%": [355], "6.0%": [357], "8.2": [360], "19.1}],": [365], "respectively;": [366], "all": [367], ".001).Proportions": [370], "discontinuing": [373], "any": [376], "reason": [377], "13.5%": [379], "27.6%": [383], "liraglutide.Gastrointestinal": [385], "events": [387], "reported": [389], "by": [390], "84.1%": [391], "82.7%": [395], "liraglutide.CONCLUSIONS": [397], "RELEVANCE": [399], "Among": [400], "obesity": [405], "diabetes,": [407], "added": [416], "counseling": [418], "activity,": [423], "resulted": [424], "68": [431], "weeks.": [432]}